GLPG2737

DRUG4 trials

Sponsors

Galapagos NV

Conditions

Autosomal Dominant Polycystic Kidney DiseaseCystic FibrosisCystic fibrosis Cystic fibrosis

Phase 1

A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.

CompletedNCT03540524

Galapagos NVCystic Fibrosis

Start: 2018-05-31End: 2019-03-11Updated: 2019-04-08

Phase 2

GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis

CompletedNCT03474042

Galapagos NVCystic Fibrosis

Start: 2017-11-29End: 2018-04-10Updated: 2018-06-11

A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

TerminatedNCT04578548

Galapagos NVAutosomal Dominant Polycystic Kidney Disease

Start: 2020-11-10End: 2023-04-04Updated: 2024-08-22

Unknown Phase

A Phase I, open-label, randomized, single-dose, two-way crossover study to compare the relative bioavailability of GLPG2737 given as a capsule formulation and an oral suspension

Active, not recruitingNL-OMON45861

Galapagos NVCystic fibrosis Cystic fibrosis

Start: 2017-05-10Target: 12Updated: 2024-02-28

Related Papers

Efficacy and safety of the cystic fibrosis transmembrane conductance regulator inhibitor GLPG2737 for autosomal dominant polycystic kidney disease: phase 2a MANGROVE study.

2026-05-27

GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN).

2019-10-0513 citations